Αρχική World News Factors Associated with COVID-19 Severity Among Patients with Cancer

Factors Associated with COVID-19 Severity Among Patients with Cancer

Petros Grivas of the Department of Medicine, Division of Medical Oncology, University of Washington Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance in Seattle, WA, US and colleagues reported on 18 March 2021 in the Annals of Oncology findings from a cohort of cancer patients with COVID-19 included in the COVID-19 and Cancer Consortium (CCC19). Among 4,966 patients with COVID-19 and a history of or active cancer, 58% were hospitalised and 14% died within 30 days. Older age, male sex, obesity, comorbidities, Black race, and Hispanic ethnicity were associated with more severe COVID-19. Furthermore, worse ECOG performance status (PS), haematologic malignancy, and recent cytotoxic chemotherapy were associated with more severe COVID-19.

The authors reported in the background that patients with cancer comprise a heterogeneous population. Better understanding of specific risk factors associated with poor COVID-19 outcomes may help guide clinical management in these patients. Leveraging detailed information from almost 5,000 cancer patients with COVID-19, researchers from an international CCC19 consortium evaluated the hypothesis that specific demographic characteristics, clinical factors, and laboratory measurements are associated with severity of COVID-19. They also explored the impact of specific anticancer therapies on COVID-19 severity and 30-day all-cause mortality.

Patients with active or history of cancer and a laboratory-confirmed SARS-CoV-2 infection between 17 March and 18 November 2020 were included in the analysis. The primary outcome was COVID-19 severity measured on a scale as uncomplicated, hospitalised, admitted to intensive care unit, mechanically ventilated, died within 30 days. Multivariable regression models included demographics, cancer status, anticancer therapy and timing, COVID-19-directed therapies, and laboratory measurements among hospitalised patients.

Median age among 4,966 included patients was 66 years, 51% were female, and 50% white. In total, 2,872 (58%) were hospitalised and 695 (14%) died. In total, 61% had cancer that was present, diagnosed, or treated within the year prior to COVID-19 diagnosis.

Older age, male sex, obesity, cardiovascular and pulmonary comorbidities, renal disease, diabetes mellitus, Black race, Hispanic ethnicity, worse PS, recent cytotoxic chemotherapy, and haematologic malignancy were associated with more severe COVID-19.

Among hospitalised patients, low or high absolute lymphocyte count, high absolute neutrophil count, low platelet count, abnormal creatinine, troponin, LDH, and CRP were associated with more severe COVID-19.

Patients diagnosed early during the COVID-19 pandemic, in particular from January to April 2020 had worser outcomes than those diagnosed later.

Specific anticancer therapies, e.g. R-CHOP, platinum combined with etoposide, and DNA methyltransferase inhibitors were associated with high 30-day all-cause mortality.

The authors concluded that older age, male sex, Black race, Hispanic ethnicity, worse PS, haematologic malignancy, and ceratin laboratory measurements were associated with poor outcomes among cancer patients with COVID-19. Some chemotherapy regimens were associated with high all-cause mortality. Although further studies are needed, caution may be required in utilising particular anticancer therapies.

These findings can inform novel translational research, clinical trial designs, and clinical decision-making for cancer patients with COVID-19. The CCC19 researchers plan further investigation into healthcare disparities, outcomes for specific cancer subtypes, and impact of particular anticancer therapies.


Grivas P, Khaki AR, Wise-Draper TM, et al. Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium. Annals of Oncology; Published online 18 March 2021. doi: https:// doi.org/10.1016/j.annonc.2021.02.024.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...